• venous
  • Enoxaparin is used to prevent deep venous thrombosis, a condition in which harmful blood clots form in the blood vessels of the legs. (mayoclinic.org)
  • In her poster presentation, Trame noted, "Enoxaparin has been extensively studied in adults on its safety and efficacy during the prevention of symptomatic thromboembolism when acute anticoagulation is required due to venous thrombosis or stroke. (medpagetoday.com)
  • We hypothesize that enoxaparin dosed as per age-appropriate algorithms is associated with an increased rate of clot resolution and decreased rate of clot progression/long-term complications in children with CHD and asymptomatic venous TE. (clinicaltrials.gov)
  • TFMP
  • The purpose of this research study is to see if enoxaparin is effective in preventing blood clots in the veins in participants who have cancer of the pancreas, colorectal, non-small cell lung, ovary, or gastric and also have high levels of tissue factor bearing microparticles in their blood (TFMP). (clinicaltrials.gov)
  • pharmacokinetic
  • Using pharmacokinetic modeling and data from 126 children -- including neonates, infants and children -- who were administered enoxaparin off-label, researchers performed pharmacokinetic analyses, said Mirjam Trame, a PHD candidate at Westfälische-Wilhelms-Universität Münster, Germany. (medpagetoday.com)
  • By pharmacokinetic modeling, the median enoxaparin trough levels of the population were predicted to be 0.095 IU/ml anti Factor Xa activity for the once-daily dosing regimen and 0.27 IU/ml anti-Factor Xa activity for the twice daily dosing," she explained in the poster. (medpagetoday.com)
  • There are important pharmacokinetic and pharmacodynamic differences between enoxaparin, other LMWHs and UFH, and therefore these molecules cannot be regarded as interchangeable. (springer.com)
  • Interactions
  • Some of the pharmacodynamic features of enoxaparin that distinguish it from UFH are a higher ratio of anti-Xa to anti-IIa activity, more consistent release of tissue factor pathway inhibitor, weaker interactions with platelets and less inhibition of bone formation. (springer.com)
  • clinical practice
  • But in clinical practice, she found that the 12-hour enoxaparin levels for the once-daily dosing regimen resulted with 0.27 IU/ml anti-Factor Xa activity -- in the same anti-Factor Xa activity as the trough levels of the twice daily dosing, leading the researchers to conclude that once daily dosing of was feasible. (medpagetoday.com)
  • regimen
  • According to these results," she reported in a poster at the American Society of Hematology meeting here, "a once-daily enoxaparin dosing regimen seems to be feasible for at least 50% of this population. (medpagetoday.com)